Drug Approval | December 27, 2025
Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated
